Modern pharmacological aspects of hyperaldosteronism therapy;Moderne pharmakologische aspekte der therapie des aldosteronismus

Internist

Volumn 47, Issue 9, 2006, Pages 953-959

  Quinkler, M ^a   Reincke, M ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Conn's syndrome; Eplerenone; Hyperaldosteronism; Hypertension; Spironolactone

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CALCIUM ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; MINERALOCORTICOID ANTAGONIST; POTASSIUM SPARING DIURETIC AGENT;

ADENOMA; ARTICLE; BLOOD PRESSURE; CREATININE BLOOD LEVEL; ELECTROLYTE BLOOD LEVEL; HUMAN; HYPERTENSION; PATIENT MONITORING; PRIMARY HYPERALDOSTERONISM; UNSPECIFIED SIDE EFFECT;

ADRENAL HYPERPLASIA, CONGENITAL; ADRENALECTOMY; ADRENOCORTICAL ADENOMA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; DIAGNOSIS, DIFFERENTIAL; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; RISK FACTORS; SPIRONOLACTONE;

EID: 33748686399     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-006-1681-0     Document Type: Article

References (30)

1. Mulatero P, Stowasser M, Loh KC et al. (2004) Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 89: 1045-1050
2. Seiler L, Reincke M (2003) The aldosterone to renin ratio in secondary hypertension. Herz 28: 686-691
3. Calhoun DA, Nishizaka MK, Zaman MA et al. (2002) Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 40: 892-896
4. Eide IK, Torjesen PA, Drolsum A et al. (2004) Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 22: 2217-2226
5. Mosso L, Carvajal C, Gonzalez A et al. (2003) Primary aldosteronism and hypertensive disease. Hypertension 42: 161-165
6. Milliez P, Girerd X, Plouin PF et al (2005) Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 45: 1243-1248
7. Quinkler M, Zehnder D, Eardley KS et al. (2005) Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria. Circulation 112: 1435-1443
8. Mihailidou AS, Funder JW (2005) Nongenomic effects of mineralocorticoid receptor activation in the cardiovascular system. Steroids 70: 347-351
9. Quinkler M, Lepenies J, Diederich S (2002) Primary hyperaldosteronism. Exp Clin Endocrinol Diabetes 110: 263-271
10. Sawka AM, Young WF, Thompson GB et al. (2001) Primary aldosteronism: factors associated with normalization of blood pressure after surgery. Ann Intern Med 135: 258-261
11. Ganguly A (1998) Current concepts - Primary aldosteronism. N Engl J Med 339: 1828-1834
12. Lim PO, Young WF, MacDonald TM (2001) A review of the medical treatment of primary aldosteronism. J Hypertens 19: 353-361
13. Young WF Jr, Klee GG (1988) Primary aldosteronism. Diagnostic evaluation. Endocrinol Metab Clin North Am 17: 367-395
14. Stowasser M, Gordon RD (2001) Familial hyperaldosteronism. J Steroid Biochem Mol Biol 78: 215-229
15. Brown JJ, Davies DL, Ferriss JB et al. (1972) Comparison of surgery and prolonged spironolactone therapy in patients with hypertension, aldosterone excess, and low plasma renin. BMJ 2: 729-734
16. Jeunemaitre X, Chatellier G, Kreft-Jais C et al. (1987) Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 60: 820-825
17. Nishizaka MK, Zaman MA, Calhoun DA (2003) Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 16: 925-930
18. Covic A, Gusbeth-Tatomir P, Goldsmith DJ (2006) Is it time for spironolactone therapy in dialysis patients? Nephrol Dial Transplant 21: 854-858
19. Horky K, Widimsky J, Hradec E et al. (1987) Long-term results of surgical and conservative treatment of patients with primary aldosteronism. Exp Clin Endocrinol 90: 337-346
20. Pitt B, Zannad F, Remme WJ et al. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341: 709-717
21. Pitt B, Remme W, Zannad F et al. (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348: 1309-1321
22. Weinberger MH, Roniker B, Krause SL, Weiss RJ (2002) Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 15: 709-716
23. Kremer D, Boddy K, Brown JJ et al. (1977) Amiloride in the treatment of primary hyperaldosteronism and essential hypertension. Clin Endocrinol (Oxf) 7: 151-157
24. Griffing GT, Melby JC (1983) The therapeutic use of a new potassium-sparing diuretic, amiloride, and a converting enzyme inhibitor, MK-421, in preventing hypokalemia associated with primary and secondary hyperaldosteronism. Clin Exp Hypertens A 5: 779-801
25. Nadler JL, Hsueh W, Horton R (1985) Therapeutic effect of calcium channel blockade in primary aldosteronism. J Clin Endocrinol Metab 60: 896-899
26. Bravo EL, Tarazi RC, Dustan HP, Fouad FM (1985) The sympathetic nervous system and hypertension in primary aldosteronism. Hypertension 7: 90-96
27. Stimpel M, Ivens K, Volkmann HP et al. (1989) Therapeutic value of calcium antagonists in autonomous hyperaldosteronism. Klin Wochenschr 67: 248-252
28. Winterberg B, Vetter W, Groth H et al. (1985) Primary aldosteronism: treatment with trilostane. Cardiology 72 (Suppl 1): 117-121
29. Tenschert W, Maurer R, Vetter H, Vetter W (1987) Primary aldosteronism by carcinoma of the adrenal cortex. Klin Wochenschr 65: 428-432
30. Allolio B, Fassnacht M (2006) Adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab (in press)